Literature DB >> 8009841

Vaccinia virus core protein VP8 is required for virus infectivity, but not for core protein processing or for INV and EEV formation.

D Wilcock1, G L Smith.   

Abstract

A recombinant vaccinia virus, vDW4, has been constructed in which the L4R gene encoding the VP8 core DNA-binding protein is inducibly regulated by IPTG (isopropyl beta-D-thiogalactopyranoside). This virus produced normal-sized plaques in the presence of IPTG, but tiny plaques in the absence of inducer. Production of infectious progeny virus was reduced by 97% when VP8 synthesis was repressed and immature virions which had defective interactions between the granular viroplasm and the surrounding virion membrane were evident. However, despite the formation of these abnormal immature virions, virus maturation was able to proceed with the production of mature intracellular naked virus and extracellular enveloped virus particles of normal density. These mature particles were produced to approximately 80% of wild-type levels, but were around 100-fold less infectious. Consistent with the formation of mature virions, the repression of VP8 synthesis did not inhibit proteolytic processing of the major core proteins p4a and p4b. These results suggest that VP8 is required for correct association of the viroplasm and the immature virion envelope and that VP8 must be present during virus assembly for the production of fully infectious progeny virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8009841     DOI: 10.1006/viro.1994.1346

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  Genome-wide analysis of vaccinia virus protein-protein interactions.

Authors:  S McCraith; T Holtzman; B Moss; S Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

2.  Vaccinia virion protein VP8, the 25 kDa product of the L4R gene, binds single-stranded DNA and RNA with similar affinity.

Authors:  C D Bayliss; G L Smith
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

3.  Vaccinia virus mutations in the L4R gene encoding a virion structural protein produce abnormal mature particles lacking a nucleocapsid.

Authors:  Desyree Murta Jesus; Nissin Moussatche; Richard C Condit
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

4.  The vaccinia virus I1 protein is essential for the assembly of mature virions.

Authors:  N Klemperer; J Ward; E Evans; P Traktman
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Inducible expression of the vaccinia virus A17L gene provides a synchronized system to monitor sorting of viral proteins during morphogenesis.

Authors:  D Rodríguez; C Risco; J R Rodríguez; J L Carrascosa; M Esteban
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Microtubule-dependent organization of vaccinia virus core-derived early mRNAs into distinct cytoplasmic structures.

Authors:  M Mallardo; S Schleich; J Krijnse Locker
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

7.  Temperature-sensitive mutant in the vaccinia virus E6 protein produce virions that are transcriptionally inactive.

Authors:  Olga Boyd; Audra L Strahl; Carson Rodeffer; Richard C Condit; Nissin Moussatche
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

8.  Vaccinia virus protein A3 is required for the production of normal immature virions and for the encapsidation of the nucleocapsid protein L4.

Authors:  Desyree Murta Jesus; Nissin Moussatche; Baron B D McFadden; Casey Paulasue Nielsen; Susan M D'Costa; Richard C Condit
Journal:  Virology       Date:  2015-03-09       Impact factor: 3.616

9.  The genome of Melanoplus sanguinipes entomopoxvirus.

Authors:  C L Afonso; E R Tulman; Z Lu; E Oma; G F Kutish; D L Rock
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Vaccinia Virus B1 Kinase Is Required for Postreplicative Stages of the Viral Life Cycle in a BAF-Independent Manner in U2OS Cells.

Authors:  Augusta Jamin; Nouhou Ibrahim; April Wicklund; Kaitlin Weskamp; Matthew S Wiebe
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.